Abstract:Circulation Research, Ahead of Print. BACKGROUND:Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disorder. However, the pathogenesis of HCM, especially its nongenetic mechanisms, remains largely unclear. TFs (transcription factors) are known to be involved in various biological processes including cell growth. We hypothesized that Sp1 (specificity protein 1), the first purified TF in mammals, plays a role in the cardiomyocyte growth and cardiac hypertrophy of HCM.METHODS:Cardiac-specific conditional knockout of Sp1 mice were constructed to investigate the role of SP1 in the heart. The echocardiography, histochemical experiment, and transmission electron microscope were performed to analyze the cardiac phenotypes of cardiac-specific conditional knockout of Sp1 mice. RNA sequencing, chromatin immunoprecipitation sequencing, and adeno-associated virus experiments in vivo were performed to explore the downstream molecules of SP1. To examine the therapeutic effect of SP1 on HCM, an SP1 overexpression vector was constructed and injected into the mutant allele of Myh6 R404Q/+ (Myh6c. 1211C>T) HCM mice. The human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) from a patient with HCM were used to detect the potential therapeutic effects of SP1 in human HCM.RESULTS:The cardiac-specific conditional knockout of Sp1 mice developed a typical HCM phenotype, displaying overt myocardial hypertrophy, interstitial fibrosis, and disordered myofilament. In addition, Sp1 knockdown dramatically increased the cell area of hiPSC-CMs and caused intracellular myofibrillar disorganization, which was similar to the hypertrophic cardiomyocytes of HCM. Mechanistically,Tuft1was identified as the key target gene of SP1. The hypertrophic phenotypes induced by Sp1 knockdown in both hiPSC-CMs and mice could be rescued by TUFT1 (tuftelin 1) overexpression. Furthermore, SP1 overexpression suppressed the development of HCM in the mutant allele of Myh6 R404Q/+ mice and also reversed the hypertrophic phenotype of HCM hiPSC-CMs.CONCLUSIONS:Our study demonstrates that SP1 deficiency leads to HCM. SP1 overexpression exhibits significant therapeutic effects on both HCM mice and HCM hiPSC-CMs, suggesting that SP1 could be a potential intervention target for HCM.

Hgs Deficiency Caused Restrictive Cardiomyopathy via Disrupting Proteostasis

Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation

Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells.

Cardiac‐specific Deletion of FDPS Induces Cardiac Remodeling and Dysfunction by Enhancing the Activity of Small GTP‐binding Proteins

Abstract 58: Modeling Pathogenesis in Familial Hypertrophic Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells

Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate is Essential for Endothelial Cell Polarity and Cerebrovascular Stability

Cardiomyocyte-restricted High-Mobility Group Box 1 (HMGB1) Deletion Leads to Small Heart and Glycolipid Metabolic Disorder Through GR/PGC-1α Signalling

Histidine-rich Ca binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function.

GHSR Deficiency Exacerbates Cardiac Fibrosis: Role in Macrophage Inflammasome Activation and Myofibroblast Differentiation

Mitochondrial Dysfunction Caused by M.2336t > C Mutation with Hypertrophic Cardiomyopathy in Cybrid Cell Lines

Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient Ipsc-Derived Cardiomyocytes with MT-RNR2 Mutation.

MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways

Deficiency of Transcription Factor SP1 Contributes to Hypertrophic Cardiomyopathy

MLP-deficient Human Pluripotent Stem Cell Derived Cardiomyocytes Develop Hypertrophic Cardiomyopathy and Heart Failure Phenotypes Due to Abnormal Calcium Handling

Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice

Gsα deficiency facilitates cardiac remodeling via CREB/ Bmp10-mediated signaling

Cardiomyocyte-specific loss of RNA polymerase II subunit 5-mediating protein causes myocardial dysfunction and heart failure

Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice

Deficiency of nuclear receptor interaction protein leads to cardiomyopathy by disrupting sarcomere structure and mitochondrial respiration

Impaired end joining induces cardiac atrophy in a Hutchinson-Gilford progeria mouse model

Identification and validation of autophagy‑related genes in hypertrophic cardiomyopathy